<p><b>OBJECTIVE</b>To evaluate the outcomes of permanent
brachytherapy combined with maximal
androgen blockade (MAB) in local intermediated-
risk prostate cancer.</p><p><b>
METHODS</b>From December 2003 to December 2009, 307
patients of local
prostate cancer were treated with
brachytherapy, 98 cases of intermediated-
risk were followed-up for 5 years and data were recorded,
aged from 58 to 84 years, average 74 years.
Serum PSA was 0.4-19.0 µg/L, average 11.2 µg/L, clinical TNM stage was T1cN0M0-T2bN0M0.
Gleason score 4-7, 6.7 in average.
Prostate volume ranged from 14 to 65 ml, average 32.1 ml. All the 98
patients underwent permanent
brachytherapy combined with MAB. Biochemical
recurrence rate, biochemical-free
survival,
tumor-specific
survival, overall
survival,
salvage therapy and
complications were analyzed.</p><p><b>RESULTS</b>Followed up for 5 years, 19 cases had biochemical
recurrence, median
recurrence period 36 months. One
patient died of
prostate cancer 45 months after
brachytherapy of all 7
patients died in 5 years. Five-years biochemical-free
recurrence rate 80.6%, overall
survival 92.9%,
tumor-specific
survival 98.9%, biochemical-free
survival 79.3%. Low-
urinary tract and rectal irritation symptoms occurred in 75 cases(76.5%).
Urinary retention occurred in 7 cases (7.1%) with
catheterization duration less than 1 week, no surgical operation were performed.
Seeds immigration to
lung in 2 cases. No serious
complications occurred.</p><p><b>CONCLUSION</b>In local intermediated-
risk prostate cancer patients, permanent
brachytherapy combined with short-term MAB can be an effective
treatment with few
complications.</p>